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Abstract
Background The course of fatigue in long-term breast cancer
survivors (BCSs) is unknown. The current study examined
chronic fatigue (CF) cross-sectionally and longitudinally in
relapse-free women up to 10 years after multimodal treatment
for BC stage II/III. The prevalence of persistent fatigue (PF:
having CF at two assessments separated by >2 years) and its
predictors were also investigated.
Methods Data from questionnaires (including the Fatigue
Questionnaire and questions regarding socio-demographics
and physical symptoms) were collected twice from 249
BCSs: 2.5–7 years post-BC diagnosis (T1) and 2.5–3 years
thereafter (T2). A physical examination including blood
sampling was performed at T1.
Results CF was diagnosed in 33% of the women at T1 and
in 39% at T2, including 57 (23%) subjects with PF. Current
psychological distress, treatment-area related discomfort
and high body mass index (BMI) were associated with CF
at T1 and predicted PF. Increased leukocyte count also
predicted PF. Treatment for mental problems prior to the
BC, increased hsCRP-level and respiratory symptoms were
associated with CF at T1 but did not predict PF.
Conclusions Women may experience fatigue up to 10 years
after multimodal BC treatment, with about one third having
CF and about one fourth having PF.
Implications for cancer survivors During follow-up, BCSs
and their doctors should maximize their efforts to reduce
psychological distress, overweight and pain within the BC-
treated area, all linked to the development of persistent
fatigue.
Keywords Breast cancer survivor.Course of chronic
fatigue.Persistent fatigue.Longitudinal study
Introduction
Fatigue is a subjective experience involving feelings of
“tiredness, weakness and/or lack of energy [1]a n dm a ya l s o
imply a subjective sense of cognitive limitations [2, 3].
Fatigue associated with cancer is “disproportionate to exercise
level and not relieved by rest” [4, 5] and has a negative
impact on the quality of life of affected individuals [1, 4, 6–9].
Fatigue is a major complaint in breast cancer survivors
(BCSs) affecting as many as 30% [1, 10–12]. Most of the
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sectional assessing the level of fatigue, but not its duration
[5]. Thus, individuals with transient fatigue could not be
separated from those with persisting symptoms. Chronic
fatigue (CF), defined as fatigue above a certain level for
6 months or longer [13, 14], thus becomes of special
relevance in cancer survivors. Further, few studies have
explored fatigue in women more than 5 years post-BC
treatment [12], and only one of these long-term studies had
a longitudinal design [11]. Therefore, knowledge about the
course of fatigue in long-term BCSs is limited.
The one long-term longitudinal study demonstrated that
depression, high blood pressure, BC-treatment including
chemo- and radiotherapy and baseline fatigue scores
predicted fatigue [11]. Also a short-term longitudinal study
showed that pre-treatment fatigue score predicted fatigue in
BCSs at follow-up 2.5 years after treatment [15]. In both
cross-sectional and short-term longitudinal studies psycho-
logical distress [1, 6, 15, 16] and possible side-effects of
BC treatment [1, 6, 7, 16–18] are consistently reported as
related to fatigue, while results are conflicting regarding the
association between post-treatment fatigue and socio-
demographic variables [1, 6], age at BC diagnosis, and
disease- and treatment-related factors [1, 6, 10, 15, 18–20].
Some studies indicate that pro-inflammatory cytokines may
play a role in the development of fatigue [21, 22], and a
prolonged immune response in fatigued BCSs has been
proposed [10, 23]. However, factors related to fatigue in
short-term longitudinal and cross-sectional studies may not
necessarily be associated with persistence of fatigue.
Thus, the aims of the present study were to investigate:
1) The course of CF in long-term BCSs assessed at two
separate time points, 2.5–7 years post-BC treatment
(T1) and 2.5–3 years after T1 (T2).
2) The prevalence of persistent fatigue (PF i.e. having CF
at both T1 and T2).
3) Which clinical factors predict PF?
We hypothesized that young age at BC diagnosis,




Prior to 2002 most cancer patients living in the southern part
of Norway (comprising about 40% of the Norwegian
population) were referred to the Norwegian Radium Hospital
(NRH) when they needed radiotherapy. In 2004/2005 (T1)
women treated for BC stage II/III during the years 1998–2002
with postoperative loco-regional radiotherapy at the NRH
were invited to attend a follow-up study on late clinical and
biochemical effects. Candidates for study inclusion were
identified from the hospital’s radiotherapy registry and had to
fulfil the following inclusion criteria: 1) age ≤75 years in
2004/2005, 2) no recurrence of BC, 3) no other cancer except
for basal cell carcinoma, carcinoma in situ of the uterine
cervix, or prior or simultaneous surgery for contra lateral BC
stage I with no adjuvant treatment.
Of the 415 invited eligible women, 317 (76%) women
completed the questionnaires and also attended an outpatient
physical examination with blood sampling at the NRH at T1.
In 2007, 310 women (registered alive) of those attending
the outpatient examination were invited by mail to
participate in a second follow-up (T2) by responding to
the same questionnaire package as at T1. At T2, 249 (80%)
eligible women returned the questionnaires (Fig. 1). Wom-
415 eligible women
317 included women answering 
the questionnaires and attending  
the outpatient examination (T1  
responders)
310 women invited
249 included women answering  
the questionnaires twice (T1 and  
T2 responders)
T1 T2
66 did not want to participate
31 did only answer the questionnaires
1 excluded because of metastasis
20 new cancer/ relapse/ death
41 did not want to participate/ 
did not return questionnaires
7 women non-eligible 
metastasis/ death
Fig. 1 Overview of the study
cohort at the two assessment
points: T1 (2004) and T2 (2007).
T1: the first assessment point
included clinical examination
and blood sampling for
biochemical analyses in addition
to the questionnaire response
406 J Cancer Surviv (2010) 4:405–414en who had completed the questionnaires both at T1 and at
T2 (N=249) were included in the present study.
Treatment modalities
The women received standardized treatment according to
national guidelines issued by the Norwegian Breast Cancer
Group. Surgical treatment consisted of modified radical
mastectomy (N=184, 74%) or breast conserving surgery
(N=65, 26%) with axillary dissection at level I–II. Most of
the women received adjuvant chemotherapy (N=199, 80%)
and/or anti-estrogen treatment (N=217, 87%) (Table 1).
The radiation target volume included the breast after breast
conserving surgery or the chest wall after modified radical
mastectomy, the ipsilateral supra- and infraclavicular fossa,
lymph nodes along the ipsilateral internal mammary artery
and the ipsilateral axilla. Prior to 2000, radiotherapy was
based on standardized field arrangements, while from 2000
and onwards, treatment was based on transverse CT-images
using a commercial treatment planning system. Radiother-
apy with standardized field arrangements was given to 87
(35%) of the BCSs and the CT-based radiotherapy to 162
(65%). Further details regarding patient selection and
treatment have been described previously [24].
Due to the unselective recruitment of patients to the
hospital and the standardized treatment they received, we
consider the sample as representative for Norwegian




Information on socio-demographics, fatigue and mental
health was obtained by questionnaires. Marital status was
dichotomized as paired (married/cohabiting) versus non-
paired (separated/divorced/widows). Level of education was
categorized as ≤10 years, 11–12 years or ≥13 years of basic
education. “Previous treatment for mental problems”
included consultations with a psychiatrist or a clinical
psychologist before the survey. A diagnosis of hypothy-
roidism and use of thyroxin were also recorded.
The fatigue questionnaire (FQ) inquires about fatigue
symptoms during the previous month compared to when
the subject last felt well [13]. It measures two underlying
constructs: 7 items assessing physical fatigue and 4 items
measuring mental fatigue (i.e. subjectively reported cogni-
tive difficulties) [13]. Each item has four response
alternatives (0–3), with higher scores implying more
fatigue. Total fatigue is defined as the sum score of all 11
items, with 33 as the maximum score.
Chalder et al suggested a cut-off point of 4 or higher on
a dichotomized scale for case definition [13] and in line
with this the raw FQ scores were dichotomized (0=0 or 1,
1=2 or 3). The FQ has an additional item assessing the
duration of the fatigue symptoms, and chronic fatigue (CF)
was defined as a sum of dichotomized scores ≥4 combined
with symptom duration of 6 months or longer [13, 14].
A recent review of instruments for assessment of cancer-
related fatigue recommended use of the FQ [25]. The FQ
has been used in numerous studies involving cancer
patients [26] with internal consistencies ≥0.85 and a stable
factor structure supporting its construct validity [13, 25].
The FQ’s Cronbach’s α’s in the present sample were 0.92
(physical fatigue), 0.87 (mental fatigue) and 0.93 (total
fatigue).
In line with prior research [22] subjects having CF at
both assessment points were defined as having persistent
fatigue (PF).
The Hospital Anxiety and Depression Scale (HADS)
[27] includes two subscales: anxiety (HADS-A) and
depression (HADS-D). Each subscale consists of seven
items. Each item has four response alternatives (0=“not
present”,3 = “severe”), giving sum scores on each subscale
from 0 to 21. In line with the author’s recommendations, a
sum score ≥8 within either scale was defined as a possible
case [27]. Scores above this threshold on one or both
subscales were combined into one variable, HADS case-
ness, classifying subjects with high levels of psychological
distress. Cronbach’s α’s in the current study were 0.85
(HADS-A) and 0.83 (HADS-D).
Missing responses in the FQ (2 subjects) and HADS (2
subjects) were replaced by an individualized mean score
calculated from the completed items for each scale, given
that at least half of the items within that scale had been
responded to.
Disease-related data and data from clinical examination
Clinical data were collected from the women’s medical
records at the NRH.
At the first assessment, an experienced oncologist scored
the presence of tissue fibrosis in the irradiated regions as
“none”, “little”, “some” and “substantial”, based upon the
LENT SOMA scoring system [28]. The women were asked
about pain within or close to the BC-treated area (0 =
“none”,1=“little”,2=“some”,3=“substantial” pain).
The scores for fibrosis and pain were dichotomized (0 =
“none/little”,1=“some/substantial”). As both the presence
of fibrosis and/or pain contribute to discomfort in the BC-
treated area, these factors were merged into one variable;
“treatment-area related discomfort” categorized as 0 =
“none/little pain and fibrosis” and 1 = “some/substantial
pain and/or some/substantial fibrosis”.
J Cancer Surviv (2010) 4:405–414 407Table 1 Characteristics of women with and without chronic fatigue at T1
a
Characteristics at T1 Women with chronic fatigue (N=82) Women without chronic fatigue (N=167) p-value
Demographic and psychosocial variables Median [range] Median [range]
Age (years) at BC
b diagnosis 51 [35–70] 52 [27–69] 0.60
Age (years) at survey 55 [39–74] 56 [30–73] 0.59
Follow up time (months) 47 [34–83] 46 [30–82] 0.92
N (%) N (%)
Marital status
Paired 60 (74) 138 (83) 0.12
Non-paired 21 (26) 29 (17)
Level of education
≤10 years 15 (18) 36 (22) 0.62
11–12 years 38 (46) 66 (40)
≥13 years 29 (35) 63 (38)
Treatment for mental problems prior to the BC
Yes 16 (20) 7 (4) <0.001
No 64 (80) 156 (96)
HADS
c caseness
Yes 35 (43) 28 (17) <0.001




d 61 (74) 123 (74) 0.90
BCS
e 21 (26) 44 (26)
Laterality
Right 32 (39) 86 (52) 0.06
Left 50 (61) 81 (49)
Anti-estrogen treatment
Yes 72 (88) 145 (87) 0.83
No 10 (12) 22 (13)
Chemotherapy
Yes 68 (83) 131 (78) 0.41
No 14 (17) 36 (22)
Type of radiotherapy
Non CT
f-based 27 (33) 60 (36) 0.64
CT-based 55 (67) 107 (64)




Normal 26 (32) 74 (44) 0.01
Overweight 31 (38) 68 (41)
Obese 25 (30) 25 (15)
Hypothyroidism 13 (16) 18 (11) 0.27
Treatment-area related discomfort
Yes 42 (52) 45 (27) <0.001
No 39 (48) 120 (73)
Respiratory symptoms
Yes 23 (28) 22 (13) 0.004
No 58 (72) 145 (87)
408 J Cancer Surviv (2010) 4:405–414The women were also asked whether they experienced
respiratory symptoms (“no”/“yes”). Objective respiratory tests
included peak expiratory flow and forced expiratory volume.
Body mass index (BMI) at T1 was calculated using the
formula BMI=weight (kg)/height (m)
2 and categorized
according to guidelines [29]: underweight (<18.5), normal
weight (18.5–24.9), overweight (25.0–29.9) and obese
(≥30). Data on weight before chemotherapy and at T1
enabled the assessment of weight changes over time.
Blood tests
Non-fasting blood samples were drawn at T1. Thyroid
blood tests (TSH-measurements) were analyzed as de-
scribed elsewhere [24]. Results on TSH were dichotomized
as ≤/>3.5 mU/L [24]. Leukocyte counts and determination
of hemoglobin were performed with CELL-DYN® 4000
(Abbott diagnostic division, U.S.A). The reference range
for leukocyte count was 3.3–11.0·10
9 /l and for hemoglobin
11.5–15.5 g/dl. Serum levels of C-reactive protein were
measured with a high-sensitivity, particle-enhanced immu-
noturbidimetric assay (hsCRP), (Roche Diagnostica, Basel,
Switzerland). The detection limit for hsCRP was 0.5 μg/l.
Statistics
Continuous variables were described using median and
(range), categorical variables with proportions and [95%
confidence intervals]. Unadjusted associations were assessed
using Mann-Whitney-Wilcoxon and Chi-square tests for
continuous and categorical variables, respectively. Correla-
tions between pairs of continuous variables were measured
with Pearson’s correlation coefficient. Confidence intervals
forproportionsofthosewithincidentalandresolvingCFatT1
and T2 were constructed using the normal distribution
approximation.
Multiple logistic regression models were fitted to
identify adjusted associations between different indepen-
dent variables and PF. Leukocyte count, hemoglobin- and
hsCRP-level were treated as continuous variables in
the logistic regression models as we assumed linearity on
the log-odds scale. Predictors with a p-value <0.1 in the
univariate analyses were entered into a multiple logistic
regression model. Two-sided p-values <0.05 were consid-
ered statistically significant. All analyses were performed
using SPSS version 15.0 (SPSS Inc, Chicago IL).
Ethics
The Regional Committee for Medical and Research Ethics
and the Norwegian Data Inspectorate approved the study.
All participants gave written informed consent.
Results
Attrition analysis
The 98 women at T1 not attending the outpatient examina-
tion did not differ significantly from the responders regarding
age at BC diagnosis, BC laterality and type of surgery or
radiotherapy. However, a significantly lower proportion of
the non-responders had been treated with chemotherapy
compared to the responders (69% vs 81%, p=0.01).
The 68 subjects attending only once did not differ
significantly from the 249 included women regarding age at
Table 1 (continued)
Characteristics at T1 Women with chronic fatigue (N=82) Women without chronic fatigue (N=167) p-value
Median [range] Median [range]
Biochemical findings
Hemoglobin (g/dl) 13.7 [9.9-16.5] 13.6 [11.0-15.8] 0.82
hsCRP (mg/l) 2.5 [0.2-23.0] 1.5 [0.2-31.0] 0.004
Leukocyte count (10
9/l) 5.5 [3.0-11.0] 5.3 [2.8-11.5] 0.09
N (%) N (%)
Se-TSH≤3.5 (mU/L) 70 (85) 146 (89) 0.49
Se-TSH>3.5 (mU/L) 12 (15) 19 (12)
aFirst assessment point
bBreast cancer
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treatment. Neither were there any significant differences
between these non-responders and the study population
regarding CF status and HADS caseness at T1.
Chronic fatigue at T1
CF was diagnosed in 33% [27–39]% (N=82), of the 249
women at T1.
Compared to the non-fatigued individuals, a significantly
higher proportion of those with CF reported previous
treatment for mental problems (4% [1–7]% vs 20% [11–
28]%) and were possible HADS cases (17% [11–22]% vs
43% [32–53]%), (p<0.001, respectively), (Table 1). Fur-
ther, women with CF experienced significantly more
treatment-area related discomfort (p<0.001) and respiratory
symptoms (p=0.004).
While 30% [21–41]% (N=25), of the women with CF
had BMI≥30 at T1, only 15% [10–20]% (N=25), of the
non-fatigued women were categorized as obese (p=0.01).
Median weight gain was 4.0 kg (−17 to 30)kg in women
with CF compared to 2.0 kg (−16 to19)kg in the non-
fatigued subjects (p=0.01).
The levels of hsCRP were significantly higher in subjects
with CF as compared to those without CF (median and range:
2.5 (0.2–23.0)mg/l vs 1.5 (0.2–31.0)mg/l [p=0.004]). A
higher hsCRP-level was also significantly associated with
treatment-area related discomfort (p<0.001).
Except for the findings on hsCRP, no significant
difference was found between women with or without CF
concerning the remaining of the biochemical tests described
in the measurements section. Nor did we find any
difference between subjects with or without CF regarding
age at BC diagnosis or at survey, marital and educational
status, different types of cancer treatment or a diagnosis of
hypothyroidism.
Even though self-reported respiratory symptoms were
significantly associated with CF, the objective respiratory
tests were not.
Previous treatment for mental problems, HADS case-
ness, treatment-area related discomfort and having respira-
tory symptoms remained significantly associated with CF in
a multiple model including all variables significantly
related to CF in Table 1.
Course of CF and factors associated with PF
Ninety-seven (39% [33–45]%) of the women had CF at T2,
including 57 individuals who also had CF at T1. The latter
women were classified as having PF. Twenty-five (10% [6–
14]%) women were diagnosed with resolving fatigue- i.e CF
only at T1, while 40 (16% [12–21]%) subjects were incident
cases with CF only at T2. At both assessment points women
with PF had significantly higher total fatigue scores than
those with chronic fatigue at either T1 or T2 (p=0.012 at
T1 and p=0.023 at T2) (Fig. 2). As expected, the total
fatigue scores at the two assessment points were significantly
correlated (Pearson correlation r=0.64, p=0.01).
In the univariate analyses previous treatment for mental
problems, HADS caseness, BMI≥30, treatment-area related
discomfort, increasing hsCRP and leukocyte count evaluated
at T1 were significant predictors for PF, while educational
and marital status reached borderline significance (Table 2).
Contrary to the findings on CF, respiratory symptoms were
not associated with PF. Neither were hemoglobin-level, an
elevated TSH or a diagnosis of hypothyroidism related to PF.
hsCRP-level was significantly associated with PF in the
univariate analysis and also strongly correlated with
treatment-area related discomfort. In the multiple analysis,
treatment-area related discomfort remained a significant
predictor while hsCRP did not reach significance.
In the final multiple model BMI≥30, treatment-area
related discomfort, HADS caseness, increasing leukocyte
count and 11–12 years of education remained significant
predictors for PF. Previous treatment for mental problems
reached borderline significance (p=0.06).
Discussion
In the current study 23% of the attending women had PF,
i.e. they were diagnosed with CF at 2.5–7 years after their



































Fig. 2 Mean total fatigue scores at T1 and T2 grouped by fatigue
status. T1: first assessment point (2004). T2: second assessment point
(2007). NF: never fatigued. CF: chronic fatigued. PF: persistent
fatigued
410 J Cancer Surviv (2010) 4:405–414Table 2 Univariate and multiple logistic regression analyses with T1
a values as independent variables and “persistent fatigue (PF)” (N=57)
versus “not persistent fatigue” (N=192, reference) as dependent variable
Univariate analysis Multiple analysis
Variables OR 95% CI p-value OR 95% CI p-value
Demographic and psychosocial variables
Age (years) at BC
b diagnosis 1.00 0.97–1.04 0.76
Follow up time, T1 1.00 0.97–1.03 0.91
Marital status
non-married vs married/co-habiting 1.86 0.93–3.70 0.08
Level of education
≤10 years
11–12 years 2.33 0.98-5.53 0.06 3.02 1.14-7.98 0.03
≥13 years 1.21 0.48-3.03 0.69 1.98 0.67-5.86 0.22
Treatment for mental problems prior to BC
yes vs no 4.24 1.76–10.24 0.001 2.92 0.97–8.82 0.06
HADS
c-caseness
yes vs no 3.90 2.07–7.35 <0.001 2.57 1.18–5.60 0.02
Cancer-related variables
BC laterality




e 0.80 0.38–1.60 0.52
Chemotherapy
yes vs no 1.06 0.51–2.25 0.87
Anti-estrogen treatment
yes vs no 0.87 0.37–2.07 0.76




overweight 1.53 0.74-3.17 0.26 1.38 0.61-3.13 0.44
obese 4.10 1.87-9.00 <0.001 3.68 1.47-9.23 0.006
Hypothyroidism
yes vs no 1.43 0.62–3.31 0.40
Treatment-area related discomfort
yes vs no 4.00 2.14–7.45 <0.001 2.49 1.23–5.07 0.01
Respiratory symptoms
yes vs no 1.73 0.85–3.55 0.13
Hemoglobin (g/dl) 1.01 0.73–1.43 0.91
hsCRP (mg/l) 1.09 1.03–1.16 0.01
Leukocyte count (10
9/l) 1.35 1.12–1.63 0.001 1.29 1.03–1.61 0.03
Se-TSH >3.5 (mU/L) 0.78 0.30–2.00 0.60
aFirst assessment point
bBreast cancer
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CF was diagnosed in 33% of the attending women at T1
and in 39% at T2. However, these proportions do not
always refer to the same individuals. While 10% had
resolving fatigue with CF only at T1, 16% were incident
cases with CF only at T2. Thus, our data demonstrate that
CF after BC treatment is not necessarily a constant
condition.
Current psychological distress, treatment-area related
discomfort and BMI≥30 were associated with CF at T1
and were also significant predictors for PF in the
multiple analyses. In our sample an increased leukocyte
count (still within the reference range) was also associ-
ated with PF. While respiratory symptoms and a higher
hsCRP-level were related to CF in the cross-sectional
study at T1, these factors did not significantly predict PF
in the multiple model. Further, individuals with PF had
significantly higher total fatigue scores at both assess-
ments compared to the scores of subjects with CF only at
either time point.
Our finding that about one third of the women had CF at
each assessment point is in line with previously published
results [1, 11]. Regarding the persistence of fatigue, one
study reported that 19% of relapse-free women were
severely fatigued both 29 months post-BC treatment and
2 years thereafter [30], while another reported that 21% of
the BCSs surveyed 5–10 years after diagnosis had
persistent fatigue [11]. The authors of the latter paper
proposed that within the 1/3 of BCSs reporting fatigue at
any time, a subgroup of women experienced “more
debilitating fatigue symptoms” [11]. This is in accordance
with our findings that subjects with PF had higher total
fatigue scores at both assessment points compared to those
with transient CF.
The findings of seeking help for mental problems prior
to the BC and current psychological distress being
associated with both CF and PF are in concordance with
this study’s hypothesis and previous research [1, 6, 11, 15,
16, 19, 31]. Additionally, discomfort in the BC-treated area,
representing both pain and/or fibrosis, was associated with
CF and PF. Bower et al demonstrated that bodily pain was
related to fatigue in women assessed up to 5 years post-BC
treatment, and it was also a marginal predictor of fatigue at
follow-up 5 years later [1, 11]. However, the location of
pain was not specified. In another study, arm and shoulder
pain was associated with fatigue post-BC treatment [18].
In addition to exploring self-reported factors, we also
evaluated several clinical variables as possible predictors for
CF and PF. We found that the median weight increase in
women with CF was twice as large as in those without CF. In
linewithpreviousresearch[6, 7] we found that high post-BC
BMI was associated with CF and a significant predictor of
PF. Thus, efforts to reduce obesity in BC-treated women may
contribute to lower their risk for developing persistent fatigue
symptoms. The association between increased BMI and PF
could also indicate a common underlying mechanism not
explored in the present study design.
We observed a strong association between high hsCRP-
level and treatment-area related discomfort. Therefore, only
treatment-area related discomfort was entered into our final
multiple logistic regression model and remained signifi-
cantly associated with PF. In the univariate analysis hsCRP-
level was a significant predictor of PF, with higher levels
being associated with PF. Further, increased leukocyte
count was associated with PF. Additionally, our data show
that women with CF had higher levels of hsCRP compared
to subjects without CF. Alexander et al also reported
increased leukocyte count and CRP in relapse-free women
with fatigue post-BC treatment, suggesting that a prolonged
inflammatory response might underlie persistent fatigue
[10]. Our data may also imply that an activated immune
system plays a role in CF and PF, which is supported by
gene expression analyses on a subsample of the women
attending the present study [23]. However, a possible
association between fatigue and inflammatory markers
should be addressed in future studies.
We found no support for our hypothesis that young age
at BC diagnosis was associated with CF or PF. Neither did
we find that a diagnosis of hypothyroidism or an elevated
TSH-level impacted on the women’s fatigue status. These
results are in agreement with earlier research stating that
abnormal thyroid function is not related to fatigue post-BC
treatment [10].
We could not demonstrate any association between CF
and PF and the BC treatment. However, all the included
women were treated for stage II/III disease with postoper-
ative radiotherapy, and most of them also received
hormones and/or chemotherapy. Thus, our study was not
optimally designed to assess the impact of different treat-
ments upon fatigue.
A limitation of the current study is that information
about the women’s fatigue status pre-BC diagnosis was not
available. Therefore, we cannot conclude that fatigue was
specifically related to BC. However, given the age-span
relevant for the current study, CF in the general Norwegian
population range from 12 to 22% [32]. Thus, CF is more
prevalent in women after multimodal BC treatment than in
the general population.
Even though not significant, our data indicate that the
proportion of women with CF increased during the study’s
time span. The women included in the current study had a
higher systemic treatment burden than the non-responders.
Therefore, a response bias caused by including subjects
with more subjective symptoms cannot be excluded. Also
in the general population the prevalence of fatigue increases
with increasing age, other co-morbidities and strains of life
412 J Cancer Surviv (2010) 4:405–414[32]. Therefore, the observed increment in CF might be due
to other factors than the BC or the BC treatment.
Also, having CF at both assessment points do not
necessarily imply that the fatigue condition has been
persistent during the whole observation period. However,
previous papers on fatigue in BCSs used a similar approach
by defining individuals with persistent fatigue as “survivors
who reported significant fatigue on at least to occasions
after cancer diagnosis and treatment” [21, 22, 33].
Definite information about the women’s pre-BC mental
health status was not available and women visiting a
psychologist/psychiatrist before their BC diagnosis were
registered as having received “previous treatment for mental
problems”.ThesurveyrunregularlybytheStatisticsNorway’s
Health Interview Survey (http://www.ssb.no) reports that 4%
of Norwegian females visited a psychologist/psychiatrist
during the past 12 months in 1998. Thus, compared to the
general Norwegian population, a considerably higher propor-
t i o n( 2 0 % )o ft h ew o m e nw i t hC Fh a dc o n s u l t e da
psychologist/psychiatrist prior to their BC diagnosis.
A recent review confirmed the association between
fatigue and depression and anxiety, but the authors
concluded that “directionality needs to be better delineated
in longitudinal studies” [34]. Also in our study, direction-
ality between CF and the associated factors is difficult to
judge as data on the attending women’s pre-BC fatigue
status were not available. However, we still consider our
findings clinically important because most of the factors
found at the first evaluation to be associated with the
persistence of fatigue are possible targets for interventions.
Each woman was clinically examined by one oncologist.
Independent oncologists examining the same individual
could have allowed for estimation of the reliability of the
ratings of fibrosis. However, the examination was per-
formed by a limited number of experienced oncologists
with a common scoring agreement supporting the reliability
of this assessment.
Due to the relatively high number of study participants it
was feasible to test multiple predictors possibly associated
with PF. However, we did not have enough subjects to fit a
model testing possible interactions between the variables.
Strengths of the current study are related to the long
follow-up time and the longitudinal design enabling
exploration of the course of CF and identification of
individuals with PF as those with CF at both assessment
points. Additional strength of the present study is the use of
the FQ. Compared to other commonly used questionnaires
assessing fatigue, the FQ has the advantage that the
duration of fatigue is queried. Only subjects with symptom
duration ≥6 months were defined as having CF, thus
separating individuals with transient fatigue from those
with more persistent symptoms. Finally, due to the
unselective recruitment of patients to the hospital during
the treatment period (1998–2002) and the standardized
treatment they received based upon the existing national
guidelines at that time, we consider the sample as
representative for Norwegian women treated for BC stage
II/III during the relevant treatment period.
Conclusions/ implications for breast cancer survivors
Women may experience fatigue up to 10 years after
multimodal BC treatment, with about one third having CF
and about one fourth having PF.
Psychological distress, high BMI and discomfort related
to the BC-treated area at the first follow-up were associated
with CF and significantly predicted persistence of CF at the
second evaluation (i.e. PF). Therefore, efforts to improve
these factors may contribute to relieve PF in BCSs.
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